These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 31530667)

  • 21. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
    Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
    Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
    Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
    Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
    Lingvay I; Desouza CV; Lalic KS; Rose L; Hansen T; Zacho J; Pieber TR
    Diabetes Care; 2018 Sep; 41(9):1926-1937. PubMed ID: 30026333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
    Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
    Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
    Saravanan P; Bell H; Braae UC; Collins E; Deinega A; Dhatariya K; Machell A; Trent A; Strzelecka A
    Adv Ther; 2024 Nov; 41(11):4266-4281. PubMed ID: 39316289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
    Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
    Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
    Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
    Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
    Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.